Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and sometimes dangerous source of food poisoning. Moderna’s ...

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older.

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...